iDose® TR helps patients with glaucoma take long-term control of high eye pressureLAGUNA HILLS, CA / ACCESSWIRE / February 20,...
IRVINE, Calif. & DENVER--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a leading global provider of medical technology and automation solutions, and UCHealth, a...
Global thought leaders join advisory team to focus on Mestag’s groundbreaking tertiary lymphoid structure (TLS) induction approach to treat solid...
Publication pinpoints triggering of cGAS/STING pathway to activate immune defense mechanisms, as well as potentiation of anti-PD-L1 immune-mediated tumor cell...
– ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2...
- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human...
Updating the Human Brain With Vital NeuroMANHATTAN, NY / ACCESSWIRE / February 17, 2024 / As the world continues to...
TORONTO, ON / ACCESSWIRE / February 16, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”),...
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add...
Chimeric Bait Receptors for Combatting Brain Cancers and Neurodegenerative Diseases Can Be Delivered via Programmed Microglial CellsLONDON, UK / ACCESSWIRE...
On track to complete enrollment of the chronic cohort in Q2 2024Data readout from chronic cohort expected in Q3 2024Planning...
Non-opioid drug candidate from Tonix lowered pain and also improved sleep and fatigueLatest Phase 3 trial achieved primary endpoint (p=0.00005)Potential...
Up to 16 million adults in the US are living with a neurological disease, the leading cause of physical and...
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel...
With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose...
Mississauga, Ontario--(Newsfile Corp. - February 13, 2024) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), an emerging player in...
Masimo MightySat® Medical Provides Clinically Proven Masimo SET® Pulse Oximetry to Consumers for Medical Use Without a PrescriptionIRVINE, Calif.--(BUSINESS WIRE)--Masimo...
Masimo MightySat® Medical Provides Clinically Proven Masimo SET® Pulse Oximetry to Consumers for Medical Use Without a PrescriptionIRVINE, Calif.--(BUSINESS WIRE)--Masimo...
STUDIO CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is excited to announce the launch...